



## OncoBioPharm appoints Dr Tina Flatau as Managing Director.

Edinburgh, Scotland. 3rd January 2016.

OncoBioPharm Limited, an innovative Scottish biotechnology company working in the field of novel cancer therapies, announced that it has appointed its advisor Dr Tina Flatau as Managing Director, effective immediately.

Chairman Professor Chris Wood said *'Tina's development experience and industry knowledge will be a great asset as we continue to grow OncoBioPharm and initiate clinical trials with Tensinomab®.*

Dr Flatau holds a PhD in Pharmaceutical Sciences from King's College London and worked in product development with SmithKlineBeecham (later GSK). She was in the first Pharmaceuticals Practice team at Coopers & Lybrand/ PwC, and has a special interest in novel biotechnology developments. Dr Flatau worked with a number of biotechs through growth-phase, acquisitions and IPO, most recently rare disease company Prosensa's successful IPO onto NASDAQ.

Dr Flatau commented *'OncoBioPharm have an exciting technology based on angiotensin modulation, and I look forward to leading our efforts to bring Tensinomab®, our lead treatment to stop cancer cell proliferation and cancer spread, into full clinical development'.*

### About OncoBioPharm

OncoBioPharm Ltd is a biotechnology company based in Scotland, developing therapeutic antibodies that target novel pathways associated with cancer cell growth and metastasis. These new targets provide OncoBioPharm with the potential to develop new powerful anti-cancer agents, with a focus on extending and improving the lives of people with cancer.

### About Tensinomab

Tensinomab, a single chain fragment variable of a monoclonal antibody, specifically targets the N-terminus of the angiotensin II Type 1 (AT1) receptor. Many major cancers over-express the AT1 receptor, which is associated with cancer cell proliferation, tumour invasion and metastasis. Tensinomab has been shown to block cell growth, invasion and metastasis in a variety of tumour models.